CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
The products will be manufactured at the company's facility in Bengaluru
The product is expected to start contributing meaningfully to the revenue from FY25
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
The Leaders of G20 met in New Delhi and committed to strengthening global health and implementing one health approach
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Subscribe To Our Newsletter & Stay Updated
